TIDMEKF

RNS Number : 5209F

EKF Diagnostics Holdings PLC

23 February 2015

EKF Diagnostics Holdings plc

("EKF", the "Company" or the "Group")

Notice of Results

Investor Results Presentations

As announced on 28 January 2015, EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed point-of-care, central laboratory and molecular diagnostics business, will announce its preliminary results for the year ended 31 December 2014 on Monday 16 March 2015.

Analyst presentation

A briefing for analysts will take place at the London Capital Club, 15 Abchurch Lane, EC4N 7BW at 9.30am on Monday 16 March 2015.

Investor presentation

A briefing for all investors will take place on Tuesday 17 March 2015 at Rocket, 6 Adams Court, Old Broad Street, London EC2N 1DX from 4:30pm for a 4.45pm start, and will be followed by drinks and canapés.

If you would like to register to attend either presentation, or require further information, please contact Lianne Cawthorne at Walbrook PR on 020 7933 8780 or email ekf@walbrookpr.com.

Enquiries:

 
EKF Diagnostics Holdings plc                             Tel: 029 2071 0570 
David Evans, Executive Chairman                          Mob: 07740 084 452 
Julian Baines, CEO                                       Mob: 07788 420 859 
Paul Foulger, CFO                                        Mob: 07710 989 255 
 
Panmure Gordon (UK) Limited 
Robert Naylor (Corporate Finance)                        Tel: 020 7886 2714 
Michael Seabrook (Sales)                                 Tel: 020 7886 2704 
 
Walbrook PR Limited                Tel: 020 7933 8780 or ekf@walbrookpr.com 
Paul McManus                                             Mob: 07980 541 893 
Lianne Cawthorne                                         Mob: 07584 391 303

About EKF Diagnostics Holdings plc - www.ekfdiagnostics.com

EKF Diagnostics Holdings plc was formed in July 2010 following the acquisition of EKF-diagnostic GmbH for EUR14.32m and refocused its strategy to one of building a substantial point of care diagnostics business. As part of this strategy, the Group has integrated three further acquisitions, Quotient Diagnostics Limited (acquired in September 2010), Argutus Medical Limited (acquired in December 2010) and Stanbio Laboratory L.P. (acquired in June 2011). In 2013 EKF established a new subsidiary, EKF Molecular Diagnostics Ltd, to focus on molecular and companion diagnostics and acquired 360 Genomics Ltd, a business that owns diagnostics technologies for cancer gene detection.

The Company, with its head office in Cardiff and operations in London, Germany, Poland, Russia, Ireland and the US, is a leading diagnostics business, focussing on the development, production and distribution of chemical reagents and analysers for the testing of Glucose, Lactate, Haemoglobin, Haematocrit and HbA1c.

In March 2011 EKF entered into a distribution agreement with Alere Inc ("Alere"), a global diagnostics company, under which Alere was appointed the exclusive distributor of EKF's CLIA waived Hemo Control device and cuvettes in the US, Canada and United Kingdom. The device is distributed in the US under the name HemoPoint H2.

In March 2014, EKF acquired Separation Technology, Inc., a Florida based manufacturer of in vitro diagnostics devices for the haematology testing market. In April 2014, EKF completed the acquisitions of Selah Genomics Inc., a US based developer of molecular diagnostics for personalised medicine and DiaSpect Medical AB., a Swedish based manufacturer of point-of-care haemoglobin analysers.

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCEAKAEADLSEFF

Ekf Diagnostics (LSE:EKF)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Ekf Diagnostics Charts.
Ekf Diagnostics (LSE:EKF)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Ekf Diagnostics Charts.